None listed
Conditions
Interventions
None listed
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) 19 years of age or older at the time of obtaining consent 2) Patients diagnosed with hormone receptor positive, HER2 overexpression negative breast cancer A. Patients diagnosed with metastatic breast cancer : those who are undergoing or scheduled to undergo palliative hormonal therapy OR B. Patients diagnosed with locally advanced breast cancer: those who have undergone neoadjuvant chemotherapy or adjuvant chemotherapy. 3) Patients for whom primary breast cancer specimens were obtained at the time of diagnosis to confirm ESR1 and PIK3CA mutations 4) Patients with confirmed clinical pathology information such as age at the time of surgery, grade, tumor size, and presence of lymph node metastasis. 5) Patients eligible for imaging tests to evaluate treatment response 6) Patients eligible for serial blood sampling during anti-hormonal treatment
Exclusion criteria
Exclusion criteria: 1) Patients diagnosed histologically with phyllodes tumor or sarcoma 2) Patients diagnosed with other cancers before breast cancer 3) Male breast cancer patient 4) Patients who have difficulty understanding research due to mental illness 5) Patients who plan to undergo follow-up at a location other than the research institution
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Predicting prognosis and treatment responsiveness by identifying ESR1 and PIK3CA mutations in the blood at the time of tumor and metastasis in patients with metastatic breast cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of real-time changes in ESR1 and PIK3CA mutations in serial ctDNA during anti-hormone treatment among metastatic breast cancer patients and clinical disease progression | — |
Countries
Korea, Republic of
Contacts
Public ContactSae Byul Lee
Asan Medical Center
Outcome results
None listed